KNOWLEDGE BANK

Interviews

Rise of Enabling Technologies in Pharmaceutical Formulation Development and Manufacturing

Director, Formulation Development, Exelixis, Inc
Kasturi Pawar is a leading pharmaceutical scientist with a PhD in pharmaceutical sciences She has significantly contributed to the field of pharmaceutics Her research and experience have been focused on formulation development drug delivery and clinical supply chain Currently working as a Director in Formulation Development at Exelixis Inc she holds several publications and patents on drug deliver...

Articles

APAC’s Biopharma Providers’ Role in Pioneering a Healthcare Revolution

Asias healthcare landscape is undergoing a transformative journey grappling with profound challenges in changing demographics persistent health inequities and the rising burden of increased disease prevalence

Research Insights

Virus-derived variation in diverse human genomes

Acquisition of genetic material from viruses by their hosts can generate interhost structural genome variation We developed computational tools enabling us to study virusderived structural variants SVs in populationscale whole genome sequencing WGS datasets and applied them to humans Although SVs had already been cataloged in these subjects

Case Studies

Local Production Of Pharmaceuticals And Related Technology Transfer In Developing Countries

Abstract As stakeholders in the Global Strategy and Plan of Action on Public Health Innovation and Intellectual Property GSPAPHI adopted by the World Health Assembly in the United Nations Conference on Trade and Development UNCTAD the World Health Organization WHO and the International Centre for Trade and Sustainable Development ICTSD are col

Techno Trends

Armata Pharmaceuticals Introduces Breakthrough AP-SA02 Therapy for Treating S. aureus Bacteremia

Armata Pharmaceuticals has introduced APSA for the adjunct treatment of complicated Staphylococcus aureus S aureus bacteremia caused by methicillinsensitive S aureus MSSA or methicillinresistant S aureus MRSA

White Papers

Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches

In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS

TOP ARTICLES

1

A Structured Review on BCRP-Mediated Multidrug Resistance

Nensi Raytthatha

Nensi Raytthatha Research Scholar, Sigma Institute of Pharmacy, Vadodara. She has published more than 5 research and review papers in reputed journals. She has presented more than 10 posters and have attended national and international conferences.

 

Isha Shah

Isha Shah, Research Scholar, Sigma Institute of Pharmacy, Vadodara. She has published five research and review papers in reputed journals. She has presented more than 10 posters and have attended national and international conferences.

 

Jigar Vyas

Jigar Vyas has more than 16 years of teaching and research experience. He has guided more than 40 PG students and has published more than 50 research and review papers. He has received of IQAC award for quality, performance in teaching and research.

 

2

A BITTER PILL: Exploring the Realm of Drug Counterfeiting

Stephen Ward

Stephen Ward is Pinkerton’s the Vice President of East Coast USA. Established in 1850, Pinkerton National Detective Agency offers organizations in today’s modern age, a range of corporate risk management services from security consulting and investigations to executive protection, employment screening and protective intelligence.

Angelo Krizmanic

Angelo Krizmanic is Pinkerton’s Vice President of Asia Pacific. Established in 1850, Pinkerton National Detective Agency offers organizations in today’s modern age, a range of corporate risk management services from security consulting and investigations to executive protection, employment screening and protective intelligence.

3

How Big Data is Transforming Clinical Trials in Asia

Atharva

I’m Atharva, a content writer currently at Consegic Business Intelligence. With over 3 years of professional experience, I've specialised as a ghostwriter for prominent companies and industry publications, exploring various topics.

4

There’s Finally Hope to Alleviate the Burden of Chronic Diseases

Raman Singh

Raman Singh oversees global pharmaceutical operations at Juniper Biologics. The company focuses on researching, developing, and commercializing novel therapies in oncology, rare diseases, and gene therapy. Under his leadership, Juniper expanded operations in Asia, Middle East, and Africa. Raman also led a US$600m acquisition of TG-C (gene therapy) and acquired oncology treatments for multiple regions.

 

5

Navigating Regulatory Frameworks: “Generic Approvals in Latin America’s Two Giants- Brazil & Mexico

Bhavya Sridevi Sundaraneedi

Sundaraneedi Bhavya Sridevi is a Master’s student of Regulatory Affairs at National Institute of Pharmaceutical Education and Research (NIPER- Raebareli). She had a six-month internship experience at Hetero Labs in Regulatory affairs of Latin America. Her interests include global regulatory affairs and Latin American emerging market regulations.

Dr. Rahul Shukla

Dr. Rahul Shukla, Assistant Professor at the Department of Pharmaceutics, NIPER Raebareli, Lucknow, an Institute of National Importance, under the Ministry of Chemicals & Fertilizers, Govt. of India. He was awarded SERB International Research Experience (SIRE) Fellow. Listed in Stanford University's Top 2% Scientists in Pharmaceutical Sciences Worldwide. 
Research Interest: Pharmaceutics, Nanomedicine, Particle Engineering, Bionanomaterials for various therapeutic applications.
 

press releasesRead more...

Chai Discovery Announces Collaboration with Roche in AI-Driven Drug Discovery

Chai Discovery the AI company building a computeraided design suite for proteinbased therapeutics today announced a collaboration with Roche to use Chais AI models and platform in a number of drug discovery programs across its therapeutic areas

PharmAla Signs Agreement and Initiates R&D with Corealis Pharma for GMP Manufacturing of its patented ALA-002 Drug Product

PharmAla Biotech Holdings Inc a biotechnology company focused on the research development and manufacturing of MDXXclass molecules including its proprietary LaNeo MDMA announces that it has signed an agreement with Corealis Pharma Inc Corealis a GMPcompliant contract development

HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Autoimmune Hemolytic Anemia

HUTCHMED China Limited announces that the US Food and Drug Administration FDA has granted Orphan Drug Designation to sovleplenib for the treatment of autoimmune hemolytic anemia AIHA Sovleplenib is a novel selective oral spleen tyrosine kinase Syk inhibitor

Abbott and Novo expand partnership to launch Plosbrio® broadening access to semaglutide for advanced diabetes care across Asia Pacific

Abbott the global healthcare leader and Novo a global leader in treatments for serious chronic diseases announced an expanded strategic collaboration to increase access to originator semaglutide for people living with type diabetes across Asia Pacific Under the agreement Abbott will commercialise

Zuellig Pharma Strengthens Clinical Sourcing Capabilities in China through Strategic Acquisition

Zuellig Pharma a leading healthcare solutions company in Asia announced the strategic acquisition of a specialized clinical supply facility in Hangzhou China strengthening its clinical sourcing capabilities to better support domestic and international clinical trials

Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.

Teva Pharmaceutical Industries Ltd and Samsung Bioepis Co Ltd today announced that they have entered into a license and commercialization agreement for two FDAapproved immunology biosimilars infliximababda a biosimilar to Remicade infliximab and ETICOVO etanerceptykro a biosimilar to Enbrel etanerc...

EventsRead more...

09 - 11

Nov 2026

11th Microbiome Movement USA Summit

The Colonnade Hotel, Boston, M...

10 - 11

Nov 2026

Extractables & Leachables Europe

Parkhotel Schӧnbrunn, Vienna,...

11 - 13

Nov 2026

Frontiers in Cancer Science 2026

One Farrer Hotel,1 Farrer Park...

11 - 12

Nov 2026

24 - 25

Nov 2026

24 - 27

Nov 2026

Pharmtech & Ingredients 2026

Crocus Expo, Pavilion 2, Mosco...

24 - 25

Nov 2026

BioPharma Deals Conference 2026

Science Congress Center, Munic...

LATEST NEWSRead more...

Johnson & Johnson Receives Approval for RYBREVANT FASPRO to Treat Advanced Head and Neck Cancer

Johnson Johnson has received accelerated approval from the US Food and Drug Administration FDA for RYBREVANT FASPRO amivantamab and hyaluronidaselpuj to treat adults with recurrent or metastatic head and neck squamous cell carcinoma HNSCC

Boehringer Ingelheim Enters into Partnership with SBP Group to Advance Next-Generation Cancer Therapies

Boehringer Ingelheim and Sino Biopharmaceutical SBP Group have entered into a multiprogram partnership to develop potential nextgeneration cancer treatments using antibodydrug conjugate ADC and Tcell engager TcE technologies

MindWalk Partners with Teva to Support Antibody Discovery Using AI

MindWalk has entered into a multiyear agreement with Teva Pharmaceuticals Australia to support antibody discovery and design optimisation using AI technology ReefIQ is MindWalks biological context platform for the life sciences sector powered by its HYFT technology The technology

CStone Enters into Collaboration with Kimia Therapeutics to Advance Clinical Development of Novel Oncology Drug

CStone Pharmaceuticals has entered into a clinical development collaboration with USbased Kimia Therapeutics to advance a potential firstinclass drug candidate targeting the DNA damage response DDR pathway which plays an important role in the survival of solid tumour cells

DKSH and The Baker Company Partner to Expand Cell Culture and Microbiology Research

DKSH Business Unit Technology has entered into an exclusive distribution agreement with The Baker Company to make its Baker Ruskinn range of controlledenvironment technologies available to laboratories across Thailand The partnership aims to improve access to equipment used in cell culture tissue c...

Fresenius Enters into Agreement with WuXi Biologics to Expand Biosimilars Pipeline

Fresenius has entered into an exclusive development agreement with WuXi Biologics to expand its biosimilars pipeline and strengthen its biopharmaceutical business The partnership will give Fresenius access to WuXi Biologics capabilities in biologics research development and manufacturing